Autoimmune Hepatitis

Autoimmune Hepatitis (AIH) is a chronic, progressive, necroinflammatory liver disease characterized by immune-mediated destruction of hepatocytes. It is clinically marked by the presence of autoantibodies, hypergammaglobulinemia, and interface hepatitis on histopathology. Without intervention, AIH progresses to cirrhosis, portal hypertension, and liver failure.

The exact cause remains idiopathic, but it is driven by a complex interplay of genetic predisposition and environmental triggers.

• Genetic Factors: Strong association with Human Leukocyte Antigens (specifically HLA-DR3 and HLA-DR4 alleles).


• Environmental Triggers: Viral infections (e.g., Epstein-Barr virus, Hepatitis A/B/C, Herpes simplex) and xenobiotics (drugs like nitrofurantoin or minocycline) can initiate molecular mimicry, breaking immune tolerance.

AIH involves a loss of self-tolerance to hepatocyte membrane antigens. Autoreactive CD4+ T-helper cells recognize self-antigenic peptides presented by MHC Class II molecules. This initiates a cellular cascade:

1. Th1 Activation: Promotes IFN-gamma secretion, activating macrophages and upregulating MHC Class I expression on hepatocytes.


2. Th17 Activation: Promotes neutrophil infiltration and tissue damage via IL-1

1. B-Cell Activation: Plasma cells produce autoantibodies (ANA, SMA, anti-LKM1).


2. Cytotoxic Destruction: CD8+ T cells and Natural Killer (NK) cells induce hepatocyte apoptosis, culminating in "interface hepatitis" (lymphoplasmacytic infiltration crossing the limiting plate).

• Prevalence: Approximately 10 to 30 per 100,000 individuals in Europe and North America.
• Gender: Strong female predominance (4:1 female-to-male ratio).
• Age: Bimodal distribution peaking in childhood/adolescence and again between ages 40 and

• Female biological sex
• HLA-DR3 or HLA-DR4 allele carrier status
• Personal or family history of other autoimmune disorders (e.g., Hashimoto’s thyroiditis, Type 1 diabetes, Celiac disease, Rheumatoid arthritis)

• Vitals: Usually stable; low-grade fever possible in acute flares.
• Inspection: Jaundice, scleral icterus, spider angiomas, palmar erythema, muscle wasting, caput medusae (in advanced cirrhosis).
• Palpation: Hepatomegaly (smooth, firm edge), splenomegaly, ascites fluid wave.
• Auscultation: Normal, unless ascites limits diaphragmatic excursion.

• Clinical Assessment: Utilizing the Simplified Diagnostic Criteria for AIH (assesses IgG, autoantibodies, exclusion of viral hepatitis, and histology).
• Laboratory Testing: Liver function panel, autoantibody screens, and immunoglobulins.
• Imaging Studies: Standard transabdominal ultrasound or elastography.
• Biopsy Findings: Lymphoplasmacytic interface hepatitis, hepatocyte rosetting, and emperipolesis (presence of an intact cell within another cell).
• Differential Diagnosis: Exclude Wilson's disease, Drug-Induced Liver Injury (DILI), Primary Biliary Cholangitis (PBC), and viral hepatitis.

Abdominal Ultrasound: Purpose: Evaluate parenchymal changes and exclude biliary obstruction. Typical Findings: Coarse hepatic echotexture, splenomegaly, or ascites. Clinical Importance: Essential first-line tool to rule out mechanical biliary pathology.
Transient Elastography (FibroScan): Purpose: Quantify liver stiffness/fibrosis. Typical Findings: Increased shear wave velocity indicating stiffness. Clinical Importance: Tracks disease progression and response to therapy non-invasively.

• Drug-Induced Liver Injury (DILI): Often mimics AIH; distinguished by complete resolution upon drug withdrawal and lack of recurrence.
• Primary Biliary Cholangitis (PBC): Marked by elevated alkaline phosphatase (ALP) and positive Anti-Mitochondrial Antibodies (AMA).
• Wilson’s Disease: Suggested by low ceruloplasmin levels, elevated 24-hour urinary copper, and Kayser-Fleischer rings.

• Cirrhosis and portal hypertension
• Esophageal and gastric variceal bleeding
• Hepatic encephalopathy
• Hepatocellular Carcinoma (HCC)
• Osteopenia/Osteoporosis (exacerbated by corticosteroid therapy)

With timely immunosuppressive treatment, 10-year survival rates exceed 80–90%. Untreated AIH has a poor prognosis, with approximately 40% of patients progressing to liver failure or decompensated cirrhosis within five years.

There are no primary prevention methods due to the idiopathic genetic-environmental pathogenesis. Secondary prevention focuses on early diagnosis and strictly adhering to maintenance immunosuppressive regimens to prevent flares.

The following homeopathic remedies have been historically indicated for symptoms associated with Autoimmune Hepatitis. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

📊 Advanced Liver Function & Fibrosis Analyzer

Comprehensive multi-metric clinical liver analyzer. Simultaneously evaluates AST, ALT, Platelets to compute De Ritis Ratio, APRI Score, and FIB-4 Index for fibrosis staging.